Katsuhiko Warita

Dr. Katsuhiko Warita


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KWKatsuhiko Warita
Katsuhiko Warita
TITakuro Ishikawa
Takuro Ishikawa
ASAkihiro Sugiura
Akihiro Sugiura
JTJiro Tashiro
Jiro Tashiro
HSHiroaki Shimakura
Hiroaki Shimakura
ZOZoltán N. Oltvai
Zoltán N. Oltvai
Epithelial-mesenchymal transition (EMT) in primary tumor cells is a key prerequisite for metastasis initiation. Statins, cholesterol-lowering drugs, can delay metastasis formation in vivo and attenuate the growth and proliferation of tumor cells in vitro. The latter effect is stronger in tumor cells with a mesenchymal-like phenotype than in those with an epithelial one. However, the effect of statins on epithelial cancer cells treated with EMT-inducing growth factors such as transforming growth factor-β (TGF-β) remains unclear. Here, we examined the effect of atorvastatin on two epithelial cancer cell lines following TGF-β treatment. Atorvastatin-induced growth inhibition was stronger in TGF-β-treated cells than in cells not thusly treated. Moreover, treatment of cells with atorvastatin prior to TGF-β treatment enhanced this effect, which was further potentiated by the simultaneous reduction in the expression of the statin target enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). Dual pharmacological targeting of HMGCR can thus strongly inhibit the growth and proliferation of epithelial cancer cells treated with TGF-β and may also improve statin therapy-mediated attenuation of metastasis formation in vivo.

21 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
NINanami Irie
Nanami Irie
KMKana Mizoguchi
Kana Mizoguchi
TWTomoko Warita
Tomoko Warita
MNMirai Nakano
Mirai Nakano
KSKasuga Sasaki
Kasuga Sasaki
KWKatsuhiko Warita
Katsuhiko Warita
Metastatic melanoma has a very poor prognosis. Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors, are cholesterol-lowering agents with a potential for cancer treatment. The inhibition of HMGCR by statins, however, induces feedback, which paradoxically upregulates HMGCR expression via sterol regulatory element-binding protein-2 (SREBP2). Dipyridamole, an antiplatelet agent, is known to inhibit SREBP2 upregulation. We aimed to demonstrate the efficacy of statin–dipyridamole combination treatment in both human and spontaneously occurring canine melanoma cell lines. The half maximal inhibitory concentration (IC50) of atorvastatin showed a 68–92% reduction when combined with dipyridamole, compared with that of atorvastatin alone. In some melanoma cell lines, cell proliferation was suppressed to almost zero by the combination treatment (≥3 μM atorvastatin). Finally, the BRAF inhibitor, vemurafenib, further potentiated the effects of the combined statin–dipyridamole treatment in BRAF V600E mutation-bearing human melanoma cell lines. In conclusion, the inexpensive and frequently prescribed statin–dipyridamole combination therapy may lead to new developments in the treatment of melanoma and may potentiate the effects of vemurafenib for the targeted therapy of BRAF V600E-mutation bearing melanoma patients. The concordance between the data from canine and human melanoma cell lines reinforces this possibility.

27 July 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
YZYaxuan Zhou
Yaxuan Zhou
JTJiro Tashiro
Jiro Tashiro
SKShiori Kamatani
Shiori Kamatani
NINanami Irie
Nanami Irie
ASAkito Suzuki
Akito Suzuki
TWTomoko Warita
Tomoko Warita
Statins are cholesterol-lowering drugs that have exhibited potential as cancer therapeutic agents. However, as some cancer cells are resistant to statins, broadening an anticancer spectrum of statins is desirable. The upregulated expression of the statin target enzyme, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), in statin-treated cancer cells is a well-known mechanism of statin resistance, which can be counteracted by the downregulation of HMGCR gene expression, or degradation of the HMGCR protein. However, the mechanism by which HMGCR degradation influences the anticancer effects of statins remain unreported. We tested the effect of the HMGCR degrader compound SR-12813 at a concentration that did not affect the growth of eight diverse tumor cell lines. Combined treatment with atorvastatin and a low concentration of SR-12813 led to lowering of increased HMGCR expression, and augmented the cytostatic effect of atorvastatin in both statin-resistant and -sensitive cancer cells compared with that of atorvastatin treatment alone. Dual-targeting of HMGCR using statins and SR-12813 (or similar compounds) could provide an improved anticancer therapeutic approach.

20 July 2023 in Adipocyte
Verified
Journal Article
Open access
DCDanang Dwi Cahyadi
Danang Dwi Cahyadi
TWTomoko Warita
Tomoko Warita
NINanami Irie
Nanami Irie
KMKana Mizoguchi
Kana Mizoguchi
JTJiro Tashiro
Jiro Tashiro
KWKatsuhiko Warita
Katsuhiko Warita
Normalization is a crucial step in gene expression analysis to avoid misinterpretation. Reverse transcription-quantitative polymerase chain reaction was used to measure the expression of 10 candidate housekeeping genes in non-differentiated (ND) and differentiated (DI) 3T3-L1 cells on days 5 and 10. We used geNorm, NormFinder, BestKeeper, RefFinder, and the ∆Ct method to evaluate expression stability. The findings revealed that (1) the expression levels of the reference genes changed over time, even in non-differentiating cells, and (2) peptidylprolyl isomerase A (Ppia) and TATA box-binding protein (Tbp) were stable reference genes for 10 days in both undifferentiated and differentiated 3T3-L1 cells. Notably, the expression of known reference genes in non-differentiating cells was altered throughout the experiment.

20 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSManjulata Singh
Manjulata Singh
KWKatsuhiko Warita
Katsuhiko Warita
TWTomoko Warita
Tomoko Warita
JFJames R. Faeder
James R. Faeder
RLRobin E. C. Lee
Robin E. C. Lee
ZOZoltan N. Oltvai
Zoltan N. Oltvai
Cell-to-cell differences in protein expression in normal tissues and tumors are a common phenomenon, but the underlying principles that govern this heterogeneity are largely unknown. Here, we show that in monolayer cancer cell-line cultures, the expression of the five metabolic enzymes of serine-glycine synthesis (SGS), including its rate-limiting enzyme, phosphoglycerate dehydrogenase (PHGDH), displays stochastic cell-to-cell variation. By contrast, in cancer cell line-derived three-dimensional (3D) microtumors PHGDH expression is restricted to the outermost part of the microtumors’ outer proliferative cell layer, while the four other SGS enzymes display near uniform expression throughout the microtumor. A mathematical model suggests that metabolic stress in the microtumor core activates factors that restrict PHGDH expression. Thus, intracellular enzyme expression in growing cell ecosystems can shift to spatially ordered patterns in 3D structured environments due to emergent cell-cell communication, with potential implications for the design of effective anti-metabolic cancer therapies.

29 November 2022 in Life Sciences
Verified
Journal Article
Open access
TWTomoko Warita
Tomoko Warita
NINanami Irie
Nanami Irie
YZYaxuan Zhou
Yaxuan Zhou
JTJiro Tashiro
Jiro Tashiro
ASAkihiro Sugiura
Akihiro Sugiura
KWKatsuhiko Warita
Katsuhiko Warita